The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

This was the stock's third consecutive day of gains.

Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a partnership to tackle ...

The Dow Jones Industrial Average (DJIA) fell as much as 677.4 points, or 1.5 per cent, to 43,950.2, while the S&P 500 dropped ...